Back to search results

Targeted Medical Therapy for Angina and Non-Obstructive Coronary Arteries

This study is investigating if specific medications can improve symptoms and quality of life for people experiencing angina (chest pain) when their main heart arteries are not blocked. You might be eligible if you have stable angina and have undergone coronary function testing at Stanford University Hospital, showing no significant blockages. The study will compare two medications, Amlodipine and Nebivolol, which target different causes of chest pain, against a placebo (an inactive substance). Participants will take one of these orally once daily for 4 weeks, after a 1-3 week period to find the right dose. Success will be measured by changes in your quality of life, assessed through questionnaires.

Study design
This is an interventional study planning to enroll 150 participants. It compares specific medications to a placebo to see their effects.
What's involved
You would take a study medication or placebo orally once daily for 4 weeks, following a 1-3 week dose adjustment period. You will also complete questionnaires at the beginning and end of the study.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be assessed at 5-7 weeks, depending on the drug titration period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06424834

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Recruiting
PHASE2Ages 18+InterventionalTreatment
Stanford University
~150 participants
Updated 2024-11-27 on ClinicalTrials.gov
What's tested:AmlodipineNebivololPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Seattle Angina Questionnaire summary score
Measured over 5-7 weeks (depending on drug titration period)

Conditions

Angina Pectoris
Microvascular Angina
Vasospastic Angina
Myocardial Bridge of Coronary Artery

Explore related trials

AnginaCoronary Microvascular DiseaseMyocardial bridge of coronary arteryVasospastic Angina

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jennifer Tremmel, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Christopher Wong, MBBS, PhD
[email protected]
(650) 725 5909
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.
Absence of significant epicardial coronary artery disease on angiography
Fractional flow reserve \> 0.80
Epicardial coronary spasm on acetylcholine testing
Microvascular spasm on acetylcholine testing
Coronary flow reserve \< 2.5
Index of microcirculatory resistance ≥ 25
Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76

Exclusion

Acute coronary syndrome less than one week prior to enrolment
Cardiomyopathy
Contraindications to beta-blockers or calcium channel blockers
Baseline systolic blood pressure \< 95 mmHg
Baseline heart rate \< 55 bpm

What this trial measures

  • Seattle Angina Questionnaire summary score5-7 weeks (depending on drug titration period)

    Change in Seattle Angina Questionnaire summary score at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.